Table 4.
Comparison of sarcoidosis patients with and without arthritis.
| Patients with arthritis (n:34) | Patients without arthritis (n:36) | p | |
|---|---|---|---|
| Female, n(%) | 26(76,5) | 24(66,7) | 0,364 |
| Age, years, mean±SD | 49,73±11,80 | 48,27±11,88 | 0,609 |
| Age of symptom onset, years, mean±SD | 42,82±11,44 | 44,02±11,34 | 0,660 |
| Age at diagnosis, years, mean±SD | 43,17±11,40 | 43,80±10,78 | 0,813 |
| Delay in diagnosis, months, median (IQR) | 3±3 | 3±2 | 0,302 |
| Smoking, n(%) | 8(23,5) | 10(27,8) | 0,684 |
| Serum ACE (U/L), median(IQR) | 60,50±50,50 | 80±48,50 | 0,062 |
| Elevated serum ACE, n(%) | 20(58,8) | 28(77,8) | 0,088 |
| Calcium(mg/dl), median (IQR) | 9,55±0,92 | 9,55±0,84 | 0,832 |
| Hypercalcemia, n(%) | 5(14,7) | 4(11,1) | 0,653 |
| Hypercalciuria, n(%) | 6(17,6) | 8(22,2) | 0,632 |
| Elevated CRP, n(%) | 25(73,5) | 18 (50) | 0,043 |
| Elevated ESR, n(%) | 23(67,6) | 15(41,7) | 0,029 |
| ANA positivity, n(%) | 11(32,4) | 10(27,8) | 0,676 |
| RF positivity, n(%) | 1(2,9) | 3(8,3) | 0,331 |
| Pulmonary involvement, n(%) | 33(97,1) | 34(94,4) | 0,589 |
| Eye involvement, n(%) | 9(26,5) | 9(25) | 0,888 |
| Skin involvement, n(%) | 22(64,7) | 12(33,3) | 0,009 |
| CNS involvement, n(%) | 1(2,9) | 3(8,3) | 0,331 |
| Liver involvement, n(%) | 2(5,9) | 2(5,6) | 0,953 |
| Bone marrow involvement, n(%) | 4(11,8) | 0(0) | 0,034 |
| Stage of sarcoidosis, n(%) Stage 1 Stage 2 Stage 3 Stage 4 |
18(52,9) 9(26,5) 5(14,7) 1(2,9) |
18(50) 15(41,7) 1(2,8) 0(0) |
0,244 |
SD: standard deviation, n: number, IQR: interquartile range, CRP: C-reactive protein, ESR: erythrocyte sedimentation rate